News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Geron Corporation Clarifies License Rights For Cancer Vaccines
February 2, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 2, 2006--Geron Corporation (Nasdaq:GERN) today provided clarification with respect to license rights granted to third parties to develop cancer vaccines targeting telomerase.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Merck & Co.
MORE ON THIS TOPIC
Layoff Tracker
Vistagen cuts workforce for second time in 2026
November 2, 2026
·
114 min read
·
BioSpace Editorial Staff
Cell therapy
Cell therapy investment grows as safety events rankle Big Pharma’s CAR T autoimmune push
November 2, 2026
·
3 min read
·
Annalee Armstrong
Drug Development
Can Saudi Arabia’s burgeoning biotech hub withstand geopolitical pressures?
November 2, 2026
·
6 min read
·
Jennifer C. Smith-Parker
Earnings
AstraZeneca employs $1.5B cost savings to reinvest back into growth
October 30, 2026
·
3 min read
·
Annalee Armstrong
